Future Directions in Multiple Myeloma: Emerging Therapies, Sequencing, and the Potential for Cure

The panel looks ahead to the next 3 to 5 years of multiple myeloma treatment, highlighting emerging strategies that could further reshape the treatment landscape. Key areas of interest include the incorporation of bispecific antibodies into frontline therapy, trials comparing CAR T-cell therapy with autologous stem cell transplantation, trispecific antibodies, in vivo CAR T-cell approaches, and the emerging role of CELMoDs as potential partner therapies for bispecific and trispecific agents. The discussion also emphasizes the growing importance of treatment sequencing, with clinicians still learning how to balance efficacy, toxicity, patient preferences, access, and treatment logistics when selecting among increasingly effective options. The panelists note that the availability of highly active T-cell redirecting therapies is enabling more meaningful head-to-head comparisons and increasingly ambitious clinical trials. They also acknowledge that significant work remains to understand and manage the unique toxicities associated with these therapies. The segment concludes with the panel's perspective that durable treatment-free remission and the possibility of cure are becoming increasingly realistic goals for selected patients with multiple myeloma.